The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) last traded at $40.05, up 0.15% from the previous session.
SRPT stock price is now -32.45% away from the 50-day moving average and -62.37% away from the 200-day moving average. The market capitalization of the company currently stands at $3.94B.
With the price target maintained at $50, Evercore ISI recently Downgraded its rating from Outperform to In-line for Sarepta Therapeutics Inc (NASDAQ: SRPT). On April 11, 2025, Wells Fargo recently initiated its ‘Overweight’ rating on the stock quoting a target price of $115, while ‘H.C. Wainwright’ rates the stock as ‘Neutral’
In other news, Nicaise Claude, Director sold 2,491 shares of the company’s stock on Mar 12 ’25. The stock was sold for $248,203 at an average price of $99.64. Upon completion of the transaction, the Director now directly owns 27,812 shares in the company, valued at $1.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 12 ’25, Director Nicaise Claude bought 2,491 shares of the business’s stock. A total of $248,226 was incurred on buying the stock at an average price of $99.65. A total of 4.98% of the company’s stock is owned by insiders.
During the past 12 months, Sarepta Therapeutics Inc has had a low of $34.10 and a high of $173.25. As of last week, the company has a debt-to-equity ratio of 1.18, a current ratio of 4.02, and a quick ratio of 2.46.
The net profit margin was -11.12% and return on equity was -23.61% for SRPT.
